sacrosidase (Sucraid)
sacrosidase is an FDA-licensed reference biologic from QOL Medical, LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2022
Reference approved
Reference product
Sucraid sacrosidase
QOL Medical, LLC
- Approved
- May 25, 2022
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for sacrosidase, in chronological order.
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
21 yr 5 mo ago
Reference approval
Approval date of the reference sacrosidase product.
4 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for sacrosidase (Sucraid)?
No 351(k) biosimilars or interchangeable biosimilars referencing sacrosidase are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.